Form 4: Sangamo Therapeutics Director Kenneth Hillan Receives Significant Equity Grant

Sangamo Therapeutics, Inc. Director Kenneth J. Hillan was granted 25,000 shares of common stock as Restricted Stock Units and 50,000 stock options on June 12, 2025, as part of his compensation.

Summary

• Kenneth J. Hillan, a Director at Sangamo Therapeutics, Inc. (SGMO), reported changes in his beneficial ownership through an SEC Form 4 filing.
• On June 12, 2025, Mr. Hillan was granted 25,000 shares of common stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs are set to fully vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders, contingent on his continuous service.
• Additionally, on the same date, he was granted 50,000 stock options with an exercise price of $0.503 per share.
• These stock options are immediately exercisable, but any unvested shares purchased are subject to repurchase rights by the Issuer.
• The shares underlying the options will vest in 12 equal monthly installments following the grant date, also subject to his continuous service.
• Following these transactions, Mr. Hillan beneficially owns 99,600 shares of common stock and 50,000 stock options.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is a positive for aligning interests and retention. It contains no negative news or unexpected events, indicating business as usual for this type of filing.

Positives

• Grant of 25,000 Restricted Stock Units (RSUs) to a director, aligning management's interests with shareholder value through equity incentives.
• Grant of 50,000 stock options with an exercise price of $0.503, providing an incentive for the director to contribute to the company's long-term stock price appreciation.
• The vesting schedules for both RSUs and stock options are tied to continuous service, promoting retention of key personnel.

Risks

• The value of the granted RSUs and stock options is subject to the future performance of Sangamo Therapeutics' stock price.
• The vesting of both RSUs and stock options is contingent on the reporting person's 'Continuous Service,' meaning forfeiture could occur if service ceases before vesting.

Future Outlook

The equity grants are forward-looking incentives, tying the director's compensation to future company performance and continued service through vesting periods extending to June 2026 for RSUs and monthly installments thereafter for options.

Industry Context

This is a standard equity compensation grant for a director in a publicly traded biotechnology or pharmaceutical company. Such grants are common practice to align director incentives with long-term shareholder value and retain talent.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options to a director is a common form of equity compensation in the biotechnology and pharmaceutical sectors, similar to practices at companies like Gilead Sciences, Amgen, or Biogen, which frequently use equity to incentivize and retain key executives and board members.
• The vesting schedule for RSUs (fully vesting on the earlier of a specific date or the day prior to the next annual meeting) is a standard approach for director equity grants, often seen in companies of similar market capitalization to Sangamo.
• The immediate exercisability of options with repurchase rights on unvested shares is also a common structure, providing flexibility while maintaining retention incentives.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders by incentivizing long-term stock price appreciation and retention.

Next Steps

• The 25,000 RSUs are expected to fully vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders.
• The 50,000 stock options will vest in 12 successive equal monthly installments following the grant date of June 12, 2025.

Key Dates

Recommendation

Keywords

Sangamo Therapeutics, SGMO, SEC Form 4, Beneficial Ownership, Restricted Stock Units, RSU, Stock Options, Equity Grant, Director Compensation, Insider Transaction, Executive Compensation